Burden and changes in HIV/AIDS morbidity and mortality in Southern Africa Development Community Countries, 1990-2017

BMC Public Health

Volumn 20, Issue 1, 2020, Pages

  Gona, Philimon N ^a   Gona, Clara M ^b   Ballout, Suha ^a   Rao, Sowmya R ^c   Kimokoti, Ruth ^d   Mapoma, Chabila C ^e   Mokdad, Ali H ^f  

^a UNIVERSITY OF MASSACHUSETTS BOSTON   (United States)

^b MGH INSTITUTE OF HEALTH PROFESSIONS   (United States)

^c BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

^d SIMMONS COLLEGE   (United States)

^e UNIVERSITY OF ZAMBIA   (Zambia)

^f UNIVERSITY OF WASHINGTON   (United States)

Author keywords

HIV AIDS; mortality; Morbidity; DALYs; SADC countries; Trends

Indexed keywords

ADULT; AFRICA; AGED; CAUSE OF DEATH; CHILD; EPIDEMIC; EPIDEMIOLOGY; FEMALE; GLOBAL DISEASE BURDEN; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIFE EXPECTANCY; MALE; MIDDLE AGED; MORTALITY; PREVALENCE; QUALITY ADJUSTED LIFE YEAR; RISK FACTOR; YOUNG ADULT;

ADULT; AFRICA, SOUTHERN; AGED; CAUSE OF DEATH; CHILD; EPIDEMICS; FEMALE; GLOBAL BURDEN OF DISEASE; HIV; HIV INFECTIONS; HUMANS; LIFE EXPECTANCY; MALE; MIDDLE AGED; PREVALENCE; QUALITY-ADJUSTED LIFE YEARS; RISK FACTORS; YOUNG ADULT;

EID: 85086051598     PISSN: None     EISSN: 14712458     Source Type: Journal    
DOI: 10.1186/s12889-020-08988-9     Document Type: Article

References (41)

1. WHO. WHO validates elimination of mother-to-child transmission of HIV and syphilis in Cuba. http://www.who.int/mediacentre/news/releases/2015/mtct-hiv-cuba/en/ (Accessed 6 July 2018).
2. Bucagu M, Muganda J. Implementing primary healthcare-based PMTCT interventions: operational perspectives from Muhima cohort analysis (Rwanda). Pan Afr Med J. 2014;18:59.
3. Injury Incidence and Prevalence Collaborators (2018). Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017GBD 2017 Disease. Lancet. 2018;392:1736-88.
4. GBD 2017 Disease and Injury Incidence and prevalence collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392:1789-858.
5. GBD 2017 DALYs and HALE collaborators. Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392:1859-192.
6. GBD HIV Collaborators. Global, regional, and national incidence, prevalence, and mortality of HIV, 1980-2017, and forecasts to 2030, for 195 countries and territories: a systematic analysis for the Global Burden of Diseases, Injuries, and Risk Factors Study 2017. Lancet HIV. 2019;6(12):e831-59 UNAIDS Global HIV & AIDS.
7. Statistics - Fact Sheet - World Aids Day, 2018. www.unaids.org/en/resources/fact-sheet (Accessed 20 Dec 2018).
8. GBD 2017 Cause of Death Collaborators. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392:1736-88.
9. Institute for Health Metrics and Evaluation (IHME). Global Burden of Disease data visualization. Seattle: IHME, University of Washington; 2017. Available from https://vizhub.healthdata.org/gbd-compare/. (Accessed 17 Mar 2020).
10. Stevens GA, Alkema L, Black RE, Boerma JT, Collins GS, Ezzati M, Grove JT, Hogan DR, Hogan MC, Horton R, Lawn JE, Marušić A, Mathers CD, Murray CJ, Rudan I, Salomon JA, Simpson PJ, Vos T, Welch V; (The GATHER Working Group). Guidelines for accurate and transparent health estimates reporting: the GATHER statement. Lancet 2016;388(10062):e19-e23.
11. Tichenor M, Sridhar D. Metric partnerships: global burden of disease estimates within the World Bank, the World Health Organization and the Institute for Health Metrics and Evaluation. Wellcome Open Res. 2019;4:35 https://doi.org/10.12688/wellcomeopenres.15011.2.
12. Bendavid E, Holmes CB, Bhattacharya J, Miller G. HIV development assistance and adult mortality in Africa. JAMA. 2012;307:2060-7.
13. Global Burden of Disease Collaborative Network. Global Burden of Disease Study 2017 (GBD 2017) Disability Weights. Seattle: Institute for Health Metrics and Evaluation (IHME); 2018.
14. Salomon JA, Haagsma JA, Davis A, de Noordhout CM, Polinder S, Havelaar AH, Cassini A, Devleesschauwer B, Kretzschmar M, Speybroeck N, Murray CJ, Vos T. Disability weights for the global burden of disease 2013 study. Lancet Glob Health. 2015;3:e712-23.
15. Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJL. Editors. Global burden of disease and risk factors. Washington (DC): the International Bank for Reconstruction and Development /the World Bank. New York: Oxford University Press; 2006.
16. GBD 2017 Mortality Collaborators. Global, regional, and national age-sex-specific mortality and life expectancy, 1950-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392:1684-735.
17. Flaxman AD, Vos T, Murray CJ. An integrative meta-regression framework for descriptive epidemiology. Seattle: University of Washington Press; 2015.
18. UNAIDS Reference Group on Estimates Modelling and Projections. Improved methods and assumptions for estimation of the HIV/AIDS epidemic and its impact: recommendations of the UNAIDS Reference Group on Estimates, Modelling and Projections; 2002. p. 16.
19. Mahy M, Brown T, Stover J, Walker N, Stanecki K, Kirungi W, Garcia-Calleja T, Ghys PD. Producing HIV estimates: from global advocacy to country planning and impact measurement, Global Health Action; 2017.
20. Amanzi P, Michelo C, Simoonga C, Dambe R, Chongwe G. Survival of people on antiretroviral treatment in Zambia: a retrospective cohort analysis of HIV clients on ART. Pan Afr Med J. 2016;15(24):144.
21. Southern African Development Community. SADC HIV and AIDS strategic framework: 2010-2015. https://www.sadc.int/issues/hiv-aids/ (Accessed 1 Dec 2018).
22. Murray CJL, Ortblad KF, Guinovart C, et al. Global, regional, and national incidence and mortality for HIV, tuberculosis, and malaria during 1990-2013: a systematic analysis for the global burden of disease study 2013. Lancet. 2014;384:1005-70.
23. Institute for Health Metrics and Evaluation (IHME). Global Burden of Disease data 359 visualization. Seattle, WA: IHME, University of Washington, 2017. Available from 360 http://stage.vizhub.healthdata.org/gbd-compare/2015/ (Accessed 18 Jan 2017).
24. UNAIDS. AIDS by the numbers 2015. www.unaids.org/sites/default/files/media_asset/AIDS_by_the_numbers_2015_en.pdf (Accessed 15 Dec 2018).
25. UNAIDS. The Gap Report 2014. www.unaids.org/en/resources/documents/2014/20140716_UNAIDS_gap_report (Accessed 21 Nov 2018).
26. Stover J, Bollinger L, Izazola JA, et al. What is required to end the AIDS epidemic as a public health threat by 2030? The Cost and Impact of the Fast-Track Approach. PLoS One. 2016;11:e0154893.
27. Chin RJ, Sangmanee D, Piergallini L. PEPFAR funding and reduction in HIV infection rates in 12 focus sub-Saharan African countries: a quantitative analysis. Int J MCH AIDS. 2015;3:150-8.
28. Renju J, Moshabela M, McLean E, et al. 'Side effects' are 'central effects' that challenge retention in HIV treatment programs in six sub-Saharan African countries: a multicountry qualitative study. Sex Transm Infect. 2017;93(Suppl 3):e052971.
29. Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J. 2011;365:493-505.
30. Rodger AJ, Cambiano V, Bruun T, et al. Sexual activity without condoms and risk of HIV transmission in sero-different couples when the HIV-positive partner is using suppressive antiretroviral therapy. JAMA. 2016;316:171-81.
31. Grulich AE, Bavinton BR, Jin F, et al. HIV Transmission in Male Sero-discordant Couples in Australia, Thailand and Brazil. Seattle: 2015 Conference on retroviruses and opportunistic infections (CROI); 2015.
32. Institute for Health Metrics and Evaluation. Financing Global Health 2017: funding universal health coverage and the unfinished HIV/AIDS agenda. Seattle: Institute for Health Metrics and Evaluation; 2018.
33. 2015 Healthcare Access and Quality Collaborators. Health Access and Quality based o mortality from causes amenable to personal healthcare in 195 countries and territories, 1990-2015: a novel analysis from the Global Burden of Disease Study 2015. Lancet. 2017;390:231-66.
34. Gona CM, McGee E, DeMarco R. "What will become of me if they take this away?" Zimbabwean Women's perceptions of "free" ART. J Assoc Nurses AIDS Care. 2016;27:667-76.
35. UNAIDS: Fast-track: ending the AIDS epidemic by 2030. www.unaids.org/en/resources/documents/2014/JC2686_WAD2014report (Accessed 29 Aug 2018).
36. Kates J, Wexler A, Lief E, UNAIDS. Donor government funding for HIV in low- and middle-income countries in 2016. www.unaids.org/en/resources/documents/2017/20170721_Kaiser_donor_funding_HIV_LMIC_2016 (Accessed 22 Jan 2019).
37. UNAIDS. UNAIDS Explainer 2018. Undetectable=Untransmittable-Public Health and HIV Viral Load Suppression. www.unaids.org/sites/default/files/media_asset/undetectable-untransmittable_en.pdf (Accessed 30 Jan 2019).
38. Jiang H, Zhou Y, Tang W Maintaining HIV care during the COVID-19 pandemic Lancet HIV 2020 Published Online April 6, 2020. https://doi.org/10.1016/S2352-3018(20)30105-3.
39. Gliddon HD, Peeling RW, Kamb ML, Toskin I, Wi TE, Taylor MM. A systematic review and meta-analysis of studies evaluating the performance and operational characteristics of dual point-of-care tests for HIV and syphilis. Sex Transm Infect. 2017;93:S3-S15.
40. Micah AE, Chen CS, Zlavog BS, Hashimi G, Chapin A, Dieleman JL. Trends and drivers of government health spending in sub-Saharan Africa, 1995-2015. BMJ Glob Health. 2019;4:e001159. https://doi.org/10.1136/bmjgh-2018-001159.
41. Oliva-Moreno J, Trapero-Bertran M. Economic impact of HIV in the highly active antiretroviral therapy era - reflections looking forward. AIDS Rev. 2018;20:226-35.